AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS
Authors: CLEMENTSMANN ML WEINHOLD K MATTHEWS TJ GRAHAM BS GORSE GJ KEEFER MC MCELRATH MJ HSIEH RH MESTECKY J ZOLLAPAZNER S MASCOLA J SCHWARTZ D SILICIANO R COREY L WRIGHT PF BELSHE R DOLIN R JACKSON S XU S FAST P WALKER MC STABLEIN D EXCLER JL TARTAGLIA J DULIEGE AM SINANGIL F PAOLETTI E
Citation: Ml. Clementsmann et al., IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS, The Journal of infectious diseases, 177(5), 1998, pp. 1230-1246
INTERMEDIATE-SIZE TRIALS FOR THE EVALUATION OF HIV VACCINE CANDIDATES- A WORKSHOP SUMMARY
Authors: RIDA W FAST P HOFF R FLEMING T
Citation: W. Rida et al., INTERMEDIATE-SIZE TRIALS FOR THE EVALUATION OF HIV VACCINE CANDIDATES- A WORKSHOP SUMMARY, Journal of acquired immune deficiency syndromes and human retrovirology, 16(3), 1997, pp. 195-203
SAFETY PROFILE OF PHASE-I AND PHASE-II PREVENTIVE HIV TYPE-1 ENVELOPEVACCINATION - EXPERIENCE OF THE NIAID AIDS VACCINE EVALUATION GROUP
Authors: KEEFER MC WOLFF M GORSE GJ GRAHAM BS COREY L CLEMENTSMANN ML VERANIKETTER N ERB S SMITH CM BELSHE RB WAGNER LJ MCELRATH MJ SCHWARTZ DH FAST P CHARRON K REYNOLDS MJ ZIMMERMAN E JONES K HARRIS M FREY SE KENNEDY DJ ISRAEL H BERRY C READ B SPITZ T PACATTE T DOLIN R REICHMAN RC LAMBERT J DEMETER L ROBERTS NJ PUGLIESE M BERGER D BURKE J SCOTT T BLACKSTONE E WRIGHT PF BRAEUNER M RYBCZYK GK CRUMBO K BATTLE W CORNELL R OWENS D JENNINGS M HARBISON MA HENSMAN BJ BARR P STABLEIN DM VOSS T PALLAS S LOMAX N KOFF W LAWRENCE D JOHNSTON M SAVARESE B WESCOTT SL
Citation: Mc. Keefer et al., SAFETY PROFILE OF PHASE-I AND PHASE-II PREVENTIVE HIV TYPE-1 ENVELOPEVACCINATION - EXPERIENCE OF THE NIAID AIDS VACCINE EVALUATION GROUP, AIDS research and human retroviruses, 13(14), 1997, pp. 1163-1177
RAY OPTICS REGIME FOR GAUSSIAN RANDOM SPHERES
Authors: MUINONEN K LAMBERG L FAST P LUMME K
Citation: K. Muinonen et al., RAY OPTICS REGIME FOR GAUSSIAN RANDOM SPHERES, Journal of quantitative spectroscopy & radiative transfer, 57(2), 1997, pp. 197-205
LIGHT-SCATTERING BY GAUSSIAN RANDOM PARTICLES - RAY OPTICS APPROXIMATION
Authors: MUINONEN K NOUSIAINEN T FAST P LUMME K PELTONIEMI JI
Citation: K. Muinonen et al., LIGHT-SCATTERING BY GAUSSIAN RANDOM PARTICLES - RAY OPTICS APPROXIMATION, Journal of quantitative spectroscopy & radiative transfer, 55(5), 1996, pp. 577-601
REPORT OF A CONSENSUS WORKSHOP, SIENA, ITALY, JUNE 3-6, 1993 - STRATEGIES FOR PREVENTION OF PERINATAL TRANSMISSION OF HIV-INFECTION
Authors: AMMANN A CHIECOBIANCHI L BRYSON Y COLL O DABIS F DEMARIA A DULIEGE AM DUSE M EHRNST A ELIA L FAST P FENJO EM GOEDERT J GUZZANTI E EVA H HOFF R JACKSON JB LOMBARDI V MOFENSON L MURPHEYCORB M NEWELL ML PARDI G PECKHAM C ROGERS M ROSSI P SCARAVELLI G SCARLATTI G SEMPRINI A STEGAGNO M STIEHM R SULLIVAN J WAHREN B WIGZELL H ZOLLAPAZNER S
Citation: A. Ammann et al., REPORT OF A CONSENSUS WORKSHOP, SIENA, ITALY, JUNE 3-6, 1993 - STRATEGIES FOR PREVENTION OF PERINATAL TRANSMISSION OF HIV-INFECTION, Journal of acquired immune deficiency syndromes and human retrovirology, 8(2), 1995, pp. 161-175
REPORT OF THE PREVENTION OF PERINATAL HIV TYPE-1 TRANSMISSION WORKSHOP - CONFERENCE SUMMARY
Authors: ROBB M BRIDGES S MMIRO F FOWLER MG FAST P MCNAMARA J
Citation: M. Robb et al., REPORT OF THE PREVENTION OF PERINATAL HIV TYPE-1 TRANSMISSION WORKSHOP - CONFERENCE SUMMARY, AIDS research and human retroviruses, 11(10), 1995, pp. 1301-1303
STUDIES ON HIV-1 VACCINES BY THE AIDS VACCINE EVALUATION GROUP (AVEG)
Authors: BELSHE RB BOLOGNESI D CLEMENTS ML COREY L FAST P GRAHAM B KEEFER M MESTECKY J MULLIGAN M
Citation: Rb. Belshe et al., STUDIES ON HIV-1 VACCINES BY THE AIDS VACCINE EVALUATION GROUP (AVEG), AIDS research and human retroviruses, 11, 1995, pp. 138-138
SCIENTIFIC AND PUBLIC-HEALTH RATIONALE FOR HIV VACCINE EFFICACY TRIALS
Authors: AHOUANTO M ANDERSON R BARBOSA J BELOQUI J BHAMARAPRAVATI N BURKE D DECASTILHO EA CLEMENTS ML COUTINHO R FAST P GIRARD M GNAORE E HAASE A JAFFE H JOHNSTON M KALEEBA N KALLINGS L LEVY JP MBIDDE M MOORE J ABBING ER SCHULTZ A THONGCHAROEN P TRIPATHY S WIGZELL H DULIEGE AM WALKER C OBIJESKI J FRANCIS D BERMAN P MANNHALTER J EXCLER JL DEWILDE M PANICALI D MERSON MH PIOT P ESPARZA J OSMANOV S HEYWARD W MANE P FERRY B SCHOPPER D
Citation: M. Ahouanto et al., SCIENTIFIC AND PUBLIC-HEALTH RATIONALE FOR HIV VACCINE EFFICACY TRIALS, AIDS, 9(3), 1995, pp. 1-4
SUMMARY OF THE WORKSHOP ON PASSIVE IMMUNOTHERAPY IN THE PREVENTION AND TREATMENT OF HIV-INFECTION
Authors: STIEHM ER MOFENSON L ZOLLAPAZNER S JACKSON B MARTIN NL AMMANN AJ AMMANN A ANDRUS L BURTON D COOMBS RW CUMMINS L DULIEGE AM FAST P FOWLER MG GOLDENTHAL K KOENIG S KOUP R MADDON P MARTIN N MATHIESON B MEYER WA NEMO G POTTS B ROSSI P PRINCE A STEIMER KS
Citation: Er. Stiehm et al., SUMMARY OF THE WORKSHOP ON PASSIVE IMMUNOTHERAPY IN THE PREVENTION AND TREATMENT OF HIV-INFECTION, Clinical immunology and immunopathology, 75(1), 1995, pp. 84-93
AIDS - MODELING EPIDEMIC CONTROL
Authors: RIDA W FAST P HOFF R BARKER L
Citation: W. Rida et al., AIDS - MODELING EPIDEMIC CONTROL, Science, 267(5202), 1995, pp. 1251-1252
OPTICAL RADIATION HAZARDS ANALYSIS OF ULTRAVIOLET HEADLAMPS
Authors: SLINEY DH FAST P RICKSAND A
Citation: Dh. Sliney et al., OPTICAL RADIATION HAZARDS ANALYSIS OF ULTRAVIOLET HEADLAMPS, Applied optics, 34(22), 1995, pp. 4912-4922
MEETING REPORT - NEUTRALIZATION OF HIV-1
Authors: GOLDING H DSOUZA MP BRADAC J MATHIESON B FAST P
Citation: H. Golding et al., MEETING REPORT - NEUTRALIZATION OF HIV-1, AIDS research and human retroviruses, 10(6), 1994, pp. 633-643
SAFETY PROFILE OF HIV VACCINATION - FIRST 1000 VOLUNTEERS OF AIDS VACCINE EVALUATION GROUP
Authors: KEEFER MC BELSHE R GRAHAM B MCELRATH J CLEMENTS ML SPOSTO R FAST P
Citation: Mc. Keefer et al., SAFETY PROFILE OF HIV VACCINATION - FIRST 1000 VOLUNTEERS OF AIDS VACCINE EVALUATION GROUP, AIDS research and human retroviruses, 10, 1994, pp. 190000139-190000140
EXPANDED SAFETY AND IMMUNOGENICITY TRIAL OF RECOMBINANT GP120 VACCINES VOLUNTEERS (AVEG PROTOCOL-201)
Authors: MCELRATH MJ COREY L CLEMENTS ML BELSHE R KEEFER M GRAHAM B SPOSTO R FAST P
Citation: Mj. Mcelrath et al., EXPANDED SAFETY AND IMMUNOGENICITY TRIAL OF RECOMBINANT GP120 VACCINES VOLUNTEERS (AVEG PROTOCOL-201), AIDS research and human retroviruses, 10, 1994, pp. 190000155-190000155
NEUTRALIZING ANTIBODY-INDUCED BY (MN OR COMBINATION MN IIIB) RGP120/HIV-1 VACCINES IN LOW-RISK VOLUNTEERS/
Authors: BELSHE RB KEEFER M GRAHAM B MATTHEWS T TWADDELL T BERMAN P FAST P
Citation: Rb. Belshe et al., NEUTRALIZING ANTIBODY-INDUCED BY (MN OR COMBINATION MN IIIB) RGP120/HIV-1 VACCINES IN LOW-RISK VOLUNTEERS/, AIDS research and human retroviruses, 10, 1994, pp. 190000156-190000156
PHASE I II TRIALS OF CANDIDATE HIV-1 VACCINES
Authors: FAST P KETTER N WALKER MC WESCOTT SL SCHULTZ AM
Citation: P. Fast et al., PHASE I II TRIALS OF CANDIDATE HIV-1 VACCINES, AIDS research and human retroviruses, 10, 1994, pp. 190000049-190000049
VACCINE-INDUCED ANTIBODIES TO NATIVE AND RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS
Authors: GORSE GJ FREY SE PATEL G NEWMAN FK BELSHE RB SCHWARTZ D CLEMENTS ML KEEFER M ROBERTS N DOLIN R MCELRATH J COREY L GRAHAM BS WRIGHT P MATTHEWS T BOLOGNESI D WALKER MC FAST P FERNIE BF
Citation: Gj. Gorse et al., VACCINE-INDUCED ANTIBODIES TO NATIVE AND RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS, Vaccine, 12(10), 1994, pp. 912-918
NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1
Authors: BELSHE RB GRAHAM BS KEEFER MC GORSE GJ WRIGHT P DOLIN R MATTHEWS T WEINHOLD K BOLOGNESI DP SPOSTO R STABLEIN DM TWADDELL T BERMAN PW GREGORY T IZU AE WALKER MC FAST P
Citation: Rb. Belshe et al., NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1, JAMA, the journal of the American Medical Association, 272(6), 1994, pp. 475-480
PHASE-I AND PHASE-II TRIALS OF CANDIDATE-PREVENTIVE HIV VACCINES
Authors: KETTER N FAST P WALKER MC WESCOTT SL SCHULTZ AM
Citation: N. Ketter et al., PHASE-I AND PHASE-II TRIALS OF CANDIDATE-PREVENTIVE HIV VACCINES, Transfusion, 34(8), 1994, pp. 731-731
INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS
Authors: BELSHE RB CLEMENTS ML KEEFER MC GRAHAM BS COREY L SPOSTO R WESCOTT S LAWRENCE D GORSE GJ KENNEDY D FREY S LAMBERT J SCHWARTZ D DOLIN R ROBERTS N MCELRATH J COOMBS J WRIGHT P KARZON D FAST P WALKER MC MESTECKY J JACKSON S STABLEIN D WOLFF M
Citation: Rb. Belshe et al., INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS, Annals of internal medicine, 121(8), 1994, pp. 584
IMMUNOLOGICAL RESPONSES IN HIV-SERONEGATIVE VOLUNTEERS TO LIVE RECOMBINANT AND SUBUNIT HIV-1 ENVELOPE VACCINES
Authors: CLEMENTS ML GRAHAM B BELSHE R DOLIN R COREY L FAST P STABLEIN D SILICIANO R BOLOGNESI D WRIGHT P GORSE G KEEFER M SCHWARTZ D MCELRATH J MATTHEWS T
Citation: Ml. Clements et al., IMMUNOLOGICAL RESPONSES IN HIV-SERONEGATIVE VOLUNTEERS TO LIVE RECOMBINANT AND SUBUNIT HIV-1 ENVELOPE VACCINES, Journal of acquired immune deficiency syndromes, 6(6), 1993, pp. 682-682
PREPARATIONS FOR HIV VACCINE EFFICACY TRIALS
Authors: VERMUND SH LAWRENCE DN FISCHER RD FAST P RIDA WN SCHRAGER LK BRADAC J SHEON AR CORDELL JR DUNBAR S BARKER LF HOFF R
Citation: Sh. Vermund et al., PREPARATIONS FOR HIV VACCINE EFFICACY TRIALS, Journal of acquired immune deficiency syndromes, 6(6), 1993, pp. 746-746
SAFETY AND IMMUNOGENICITY OF GENENTECH-IIIB RGP 120 HIV-1/
Authors: SCHWARTZ D CLEMENTS ML HOPKINS J BERMAN P DULIEGE AM TWADELL T AMMANN A BELSHE R GORSE G MATTHEWS T BOLOGNESI D FAST P SPOSTO R STABLEIN D
Citation: D. Schwartz et al., SAFETY AND IMMUNOGENICITY OF GENENTECH-IIIB RGP 120 HIV-1/, AIDS research and human retroviruses, 9, 1993, pp. 190000112-190000112
SAFETY AND IMMUNOGENICITY OF LAMBDA-BACULOVIRUS DERIVED HIV-1 IIIB RECOMBINANT GP160 VACCINE (VAXSYN(R)) IN HUMANS
Authors: KEEFER M BELSHE R CLEMENTS M GRAHAM B COREY L BOLOGNESI D STABLEIN D FAST P MONTEFIORI D SMITH G DOLIN R
Citation: M. Keefer et al., SAFETY AND IMMUNOGENICITY OF LAMBDA-BACULOVIRUS DERIVED HIV-1 IIIB RECOMBINANT GP160 VACCINE (VAXSYN(R)) IN HUMANS, AIDS research and human retroviruses, 9, 1993, pp. 190000113-190000113
Risultati: 1-25 | 26-27